Key terms
About ATOS
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ATOS news
Apr 15
12:05pm ET
Promising Synergies: Atossa Therapeutics’ Advances in ER+/HER2- Breast Cancer Treatment
Apr 15
8:34am ET
Atossa Therapeutics, Quantum Leap announces initiation of I-SPY 2 trial
Apr 03
3:20pm ET
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)
Apr 03
2:01am ET
Navigating Choppy Waters: Atossa Therapeutics’ Struggle with Compliance Costs and Business Performance
Apr 02
6:26am ET
Optimistic Outlook for Atossa Therapeutics’ Z-endoxifen in Breast Density and Cancer Therapy
Mar 22
11:33am ET
Biotech Alert: Searches spiking for these stocks today
Mar 21
9:29am ET
Atossa Therapeutics provides five-year (Z)-endoxifen update
Mar 19
8:39am ET
Atossa Therapeutics provides five-year Z-Endoxifen treatment update
Mar 18
8:35am ET
Atossa Therapeutics regains compliance with Nasdaq minimum bid price rule
Mar 12
8:43am ET
Atossa Therapeutics Appoints Dr. Cigler, Expands Board Governance
Mar 12
8:43am ET
Atossa Therapeutics appoints Tessa Cigler to board of directors
Feb 22
8:38am ET
Atossa Therapeutics announces first patient dosing of Z-endoxifen
Feb 12
6:09am ET
Atossa Therapeutics initiated with a Buy at H.C. Wainwright
Feb 08
2:16pm ET
Atossa Therapeutics: A Promising Contender in Breast Cancer Therapy with Solid Financials
Feb 07
8:42am ET
Atossa announces full enrollment of Z-endoxifen arm of I-SPY 2 trial
No recent press releases are available for ATOS
ATOS Financials
Key terms
Ad Feedback
ATOS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ATOS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range